EUROPE AND JAPAN ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dogs and Other Pets}, Birds Allergy and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (Europe and Japan) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022
Code : CMI5037
Pages :508
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Market players are conducting clinical trials for development of treatment for allergy immunotherapy. This is expected to drive growth of the Europe and Japan allergy immunotherapy market over the forecast period.

Market players are conducting clinical trials for development of immunotherapy treatment for various allergies like allergic rhinitis, pet allergies, food allergies etc. for instance, the following table shows some of the clinical trials that are being conducted by the market players for allergy immunotherapy.

Key players are engaged in receiving approvals for their products from regulatory authorities and this is expected to drive growth of the Europe and Japan allergy immunotherapy market over the forecast period.

Increasing number of marketing authorizations by regulatory authorities, is expected to increase growth of market, over the forecast period. For instance, in 2018, HAL Allergy B.V. received the registration of SUBLIVAC Birch 40.000 AUN/ml and SUBLIVAC Trees 40.000 AUN/ml in Germany. The marketing authorizations were granted by German Therapieallergene Verordnung (TAV), which is the German Federal Ministry of Health, which regulates the marketing authorization requirements for the frequent therapeutic allergens.

Competitive Landscape: Major players operating in the Europe and Japan allergy immunotherapy market include Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., and DESENTUM OY.